relma-cel
Cell therapyexperimental
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 24, 2023 (NCT05765006)
Timeline
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06479356 | Phase 2 | Aug 15, 2024 | Shanghai Ming Ju Biotechnology Co., Ltd. |
| NCT06414135 | Phase 1 | Jun 12, 2024 | Jiao Tong University, Shanghai Ming Ju Biotechnology Co., Ltd. |
| NCT06365671 | Phase 2 | Apr 16, 2024 | Jiao Tong University |
| NCT06297408 | Phase 1 | Mar 31, 2024 | Chinese Academy of Medical Sciences, Shanghai Ming Ju Biotechnology Co., Ltd. |
| NCT06876688 | Phase 2 | Nov 30, 2023 | Jiao Tong University |
| NCT05765006 | Phase 1 | Feb 24, 2023 | Huazhong University of Science and Technology, Jiao Tong University, Shanghai Ming Ju Biotechnology Co., Ltd. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiao Tong University | Academic/Hospital | 4 | 3 | 2 | 2023 |
| Shanghai Ming Ju Biotechnology Co., Ltd. | Government | 4 | 3 | 2 | 2023 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1